WHO guidelines on pharmaceutical pricing policies

Home/Guidelines | Posted 24/09/2021 post-comment0 Post your comment

The World Health Organization (WHO) has issued a new plain language summary on country pharmaceutical pricing policies, as part of its efforts to promote the use of high-quality generic and biosimilar medicines.

Pay for Delay DrugsMoneyGeneric V13F21

WHO outlines policies and initiatives that could promote the use of quality generics and biosimilars in a new plain language summary of its Guideline on Country Pharmaceutical Pricing Policies (2015).

The document explains that multiple policies are necessary to achieve low prices and increase uptake of generics and biosimilars, and that promoting the use of these drugs improves access to lower‐priced equivalents of brand-name drugs.

It also explains that while promoting generics and biosimilars increases market competition and improves health equity, there is currently limited regulatory capacity to ensure the quality of generics and biosimilars, which can undermine public trust in them.

WHO makes several recommendations for policymakers responsible for promoting access to generics and biosimilars, including that countries:

• Enable early market entry of generics and biosimilars through administrative and legislative measures, e.g. encouraging early submission of regulatory applications and providing prompt review.
• Use multiple pricing policies to achieve low prices for generics and biosimilars, e.g. internal reference pricing, mark‐up regulation, tendering and lower patient co‐payments.
• Enforce a suite of policies to maximize uptake of generics and biosimilars, such as:

– legislation to allow generics (and, where appropriate, biosimilars) substitution by dispensers,
– legislation and incentives for prescribers to prescribe using International Nonproprietary Name instead of brand name,
– dispensing fees that encourage the use of generics and biosimilars,
– regressive mark-up where lower mark‐ups are applied for higher‐priced products and incentives are applied for dispensers,
– educational programmes on the quality and safety of generics and biosimilars for patients and healthcare professionals.

Examples of policies already implemented to promote the use of generics and biosimilars include removing regulatory barriers, using voluntary licence agreements, and implementing specific pricing policies (such as internal reference pricing). On the demand-side, policies include having lower patient co‐payments for generics, compulsory substitution of generics and biosimilars, and educational campaigns to raise awareness.

WHO highlights the fact that, while policies to promote generics have existed globally since the 1990s, most policies promoting the use of biosimilars are in higher-income countries in Europe.

In Italy for example, the medicines agency has recently published new guidelines for the pricing and reimbursement of medicines, including a streamlined process for generics and biosimilars [1]. In Germany, biosimilars quotas have been used to influence uptake [2].

Related articles
The role of authorized generics in improving access to medicines

Collaboration between regulatory authorities for biosimilars

Regulatory issues related to quality of biosimilars

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: Compras federales de medicamentos biológicos para el cáncer en Brasil

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Compras federales de medicamentos biológicos para el cáncer en Brasil

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

  
References
1. GaBI Online - Generics and Biosimilars Initiative. Italy publishes new guidelines on pricing and reimbursement of generics and biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Sep 17]. Available from: www.gabionline.net/guidelines/Italy-publishes-new-guidelines-on-pricing-and-reimbursement-of-generics-and-biosimilars 
2. GaBI Online - Generics and Biosimilars Initiative. Influence of local policy measures and practices on biosimilar/originator market dynamics in Germany [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Sep 17]. Available from: www.gabionline.net/biosimilars/research/Influence-of-local-policy-measures-and-practices-on-biosimilar-originator-market-dynamics-in-Germany

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: World Health Organization

comment icon Comments (0)
Post your comment
Related content
FDA updates generics guidance due to COVID-19 pandemic
34 AA010660
Home/Guidelines Posted 01/10/2021
Mexico introduces new decree on health regulation
Regulation-V13H16
Home/Guidelines Posted 27/08/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010